PeptideStack
5.2kquestions
20kanswers
220users

Is AST worth drawing at baseline before starting survodutide?

Asked 26 Oct 2025Modified 9 months agoViewed 11k times
26

The particulars: AST · survodutide.

I would like to define my thresholds before I have a result, for obvious reasons.

I want a plan with explicit stopping rules, not just steps.

How do I make this decision on evidence rather than on feel?

bloodwork
bloodwork

Laboratory monitoring: which panels are worth ordering, sensible intervals, reference-range versus optimal-range arguments, and how to read a…

296 questionsharm-reduction
harm-reduction

Reducing avoidable risk where a decision has already been made: independent verification before use, sterility practice, dose arithmetic checked…

472 questionsa1c
a1c

Glycated haemoglobin as a ninety-day glycaemic average: what a change of half a point means, why it lags, and the conditions under which it…

122 questionsliver-enzymes
liver-enzymes

ALT, AST, GGT and ALP: what they do and do not indicate about hepatic fat, why enzymes are a poor surrogate for histology, and where non-invasive…

91 questionssurvodutide
survodutide

A GLP-1 and glucagon receptor dual agonist with a substantial published MASH dataset. Use this tag for its hepatic endpoints, its dose ladder, and…

225 questions
shareeditfollowflag
NO
askednkem_obiora39k3826 Oct 2025
4Voting to keep this open — it is more specific than it first looks. – tobias_maartens 9 months ago
add a comment

No answers yet

This question has not been answered. It has been viewed 11k times, which suggests the question is of interest and the answer is not obvious. If you can answer it with a source or a worked calculation, it will be read. See how to ask and answer.
Sponsored

PeptideMeter - Independent Peptide Analytics

Aggregated, published test results and vendor ratings built from submitted batches. Methodology stated, dataset browsable, no listing fees.

Browse results

Your answer

Ask PeptideStack is a static archive. Posting is closed, but the norms are worth stating: answer the question that was asked, show your working, cite the trial or the certificate, and say plainly where the evidence runs out.

Not medical advice. Research-use-only compounds are not approved for human use.